Cargando…
Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge
BACKGROUND: The objective of the present study was to elucidate the humoral and cellular immune response mechanisms by which a reformulated inactivated chimeric PCV1-2 vaccine reduces the PCV2 viremia. Forty PCV2 seronegative 3-week-old pigs were randomly divided into the following four groups: vacc...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528477/ https://www.ncbi.nlm.nih.gov/pubmed/23078878 http://dx.doi.org/10.1186/1746-6148-8-194 |
_version_ | 1782253834147463168 |
---|---|
author | Seo, Hwi Won Oh, Yeonsu Han, Kiwon Park, Changhoon Chae, Chanhee |
author_facet | Seo, Hwi Won Oh, Yeonsu Han, Kiwon Park, Changhoon Chae, Chanhee |
author_sort | Seo, Hwi Won |
collection | PubMed |
description | BACKGROUND: The objective of the present study was to elucidate the humoral and cellular immune response mechanisms by which a reformulated inactivated chimeric PCV1-2 vaccine reduces the PCV2 viremia. Forty PCV2 seronegative 3-week-old pigs were randomly divided into the following four groups: vaccinated challenged (T01), vaccinated non-challenged (T02), non-vaccinated challenged (T03), and non-vaccinated non-challenged (T04) animals. The pigs in groups T01 and T02 were immunized with a reformulated inactivated chimeric PCV1-2 vaccine (Fostera™ PCV; Pfizer Animal Health) administered as a 2.0 ml dose at 21 days of age. At 35 days of age (0 days post-challenge), the pigs in groups T01 and T03 were inoculated intranasally with 2 ml each of PCV2b. RESULTS: A reduction of PCV2 viremia coincided with the appearance of both PCV2-specific neutralizing antibodies (NA) and interferon-γ-secreting cells (IFN-γ-SCs) in the vaccinated animals. However, the presence of anti-PCV2 IgG antibodies did not correlate with the reduction of PCV2 viremia. Lymphocyte subset analysis indicated that the numbers of CD3(+) and CD4(+) cells increased in vaccinated animals but the numbers of CD4(+) cells decreased transiently in non-vaccinated animals. The observation of a delayed type hypersensitivity response in only the vaccinated animals also supports a CD4(+) cell-associated protective cellular immune response induced by the reformulated inactivated chimeric PCV1-2 vaccine. CONCLUSIONS: The induction of PCV2-specific NA and IFN-γ-SCs, and CD4(+) cells by the reformulated inactivated chimeric PCV1-2 vaccine is the important protective immune response leading to reduction of the PCV2 viremia and control of the PCV2 infection. To our knowledge this is the first demonstration of protective humoral and cellular immunity induced by the reformulated inactivated chimeric PCV1-2 vaccine and its effect on reduction of PCV2 viremia by vaccination. |
format | Online Article Text |
id | pubmed-3528477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35284772013-01-03 Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge Seo, Hwi Won Oh, Yeonsu Han, Kiwon Park, Changhoon Chae, Chanhee BMC Vet Res Research Article BACKGROUND: The objective of the present study was to elucidate the humoral and cellular immune response mechanisms by which a reformulated inactivated chimeric PCV1-2 vaccine reduces the PCV2 viremia. Forty PCV2 seronegative 3-week-old pigs were randomly divided into the following four groups: vaccinated challenged (T01), vaccinated non-challenged (T02), non-vaccinated challenged (T03), and non-vaccinated non-challenged (T04) animals. The pigs in groups T01 and T02 were immunized with a reformulated inactivated chimeric PCV1-2 vaccine (Fostera™ PCV; Pfizer Animal Health) administered as a 2.0 ml dose at 21 days of age. At 35 days of age (0 days post-challenge), the pigs in groups T01 and T03 were inoculated intranasally with 2 ml each of PCV2b. RESULTS: A reduction of PCV2 viremia coincided with the appearance of both PCV2-specific neutralizing antibodies (NA) and interferon-γ-secreting cells (IFN-γ-SCs) in the vaccinated animals. However, the presence of anti-PCV2 IgG antibodies did not correlate with the reduction of PCV2 viremia. Lymphocyte subset analysis indicated that the numbers of CD3(+) and CD4(+) cells increased in vaccinated animals but the numbers of CD4(+) cells decreased transiently in non-vaccinated animals. The observation of a delayed type hypersensitivity response in only the vaccinated animals also supports a CD4(+) cell-associated protective cellular immune response induced by the reformulated inactivated chimeric PCV1-2 vaccine. CONCLUSIONS: The induction of PCV2-specific NA and IFN-γ-SCs, and CD4(+) cells by the reformulated inactivated chimeric PCV1-2 vaccine is the important protective immune response leading to reduction of the PCV2 viremia and control of the PCV2 infection. To our knowledge this is the first demonstration of protective humoral and cellular immunity induced by the reformulated inactivated chimeric PCV1-2 vaccine and its effect on reduction of PCV2 viremia by vaccination. BioMed Central 2012-10-19 /pmc/articles/PMC3528477/ /pubmed/23078878 http://dx.doi.org/10.1186/1746-6148-8-194 Text en Copyright ©2012 Seo et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Seo, Hwi Won Oh, Yeonsu Han, Kiwon Park, Changhoon Chae, Chanhee Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge |
title | Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge |
title_full | Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge |
title_fullStr | Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge |
title_full_unstemmed | Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge |
title_short | Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge |
title_sort | reduction of porcine circovirus type 2 (pcv2) viremia by a reformulated inactivated chimeric pcv1-2 vaccine-induced humoral and cellular immunity after experimental pcv2 challenge |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528477/ https://www.ncbi.nlm.nih.gov/pubmed/23078878 http://dx.doi.org/10.1186/1746-6148-8-194 |
work_keys_str_mv | AT seohwiwon reductionofporcinecircovirustype2pcv2viremiabyareformulatedinactivatedchimericpcv12vaccineinducedhumoralandcellularimmunityafterexperimentalpcv2challenge AT ohyeonsu reductionofporcinecircovirustype2pcv2viremiabyareformulatedinactivatedchimericpcv12vaccineinducedhumoralandcellularimmunityafterexperimentalpcv2challenge AT hankiwon reductionofporcinecircovirustype2pcv2viremiabyareformulatedinactivatedchimericpcv12vaccineinducedhumoralandcellularimmunityafterexperimentalpcv2challenge AT parkchanghoon reductionofporcinecircovirustype2pcv2viremiabyareformulatedinactivatedchimericpcv12vaccineinducedhumoralandcellularimmunityafterexperimentalpcv2challenge AT chaechanhee reductionofporcinecircovirustype2pcv2viremiabyareformulatedinactivatedchimericpcv12vaccineinducedhumoralandcellularimmunityafterexperimentalpcv2challenge |